Literature DB >> 16495247

Interlaboratory comparison of PCR-based methods for detection of penicillin G susceptibility in Neisseria meningitidis.

Muhamed-Kheir Taha1, Maria Leticia Zarantonelli, Arianna Neri, Rocío Enriquez, Julio A Vázquez, Paola Stefanelli.   

Abstract

We carried out a study for the nonculture detection of susceptibility of Neisseria meningitis to penicillin G in three laboratories of the European Monitoring Group on Meningococci (EMGM). Thirteen clinical samples (cerebrospinal fluids) and corresponding bacterial isolates from 13 cases of invasive meningococcal infection were distributed to the three laboratories. The MICs of penicillin G were determined for the isolates. Each laboratory used an "in-house" PCR-based method to determine alterations to the penA gene, which is associated with a reduced susceptibility to penicillin G. Nucleotide sequences from the 3' end of the penA gene were also determined. We observed a good correlation between genotyping of penA and the phenotypic determination (MIC) of susceptibility to penicillin G. The results obtained by the three methods for penA in the samples correlated very well with those obtained in bacterial isolates and with sequence data. The kappa coefficient that was used to estimate the level of agreement between genotypic results varied between 0.65 and 1, indicating a good agreement. This suggests that genotyping can predict susceptibility of N. meningitidis to penicillin G. These data strongly suggest that genotyping of penA should be used to determine meningococcal susceptibility to penicillin G in culture-negative cases. Although the nucleotide sequence of penA may be the gold standard in genotyping of penA, the less expensive PCR-based approach reported in this study may be quicker when a large number of isolates and clinical samples need to be tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495247      PMCID: PMC1426420          DOI: 10.1128/AAC.50.3.887-892.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Description of new mutations in the rpoB gene in rifampicin-resistant Neisseria meningitidis selected in vitro in a stepwise manner.

Authors:  Oliver Nolte; Matthias Müller; Stephan Reitz; Sandra Ledig; Ingrid Ehrhard; Hans-Günther Sonntag
Journal:  J Med Microbiol       Date:  2003-12       Impact factor: 2.472

2.  Meningococci moderately resistant to penicillin.

Authors:  J A Saez Nieto; J A Vazquez; C Marcos
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

3.  A pharmacologic evaluation of penicillin in children with purulent meningitis.

Authors:  J P Hieber; J D Nelson
Journal:  N Engl J Med       Date:  1977-08-25       Impact factor: 91.245

4.  Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA.

Authors:  H Abdillahi; J T Poolman
Journal:  Microb Pathog       Date:  1988-01       Impact factor: 3.738

Review 5.  Resistance to antibiotics mediated by target alterations.

Authors:  B G Spratt
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

6.  Properties of penicillin-binding proteins in Neisseria gonorrhoeae.

Authors:  A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia.

Authors:  Tiffany R Shultz; John W Tapsall; Peter A White; Catherine S Ryan; Dena Lyras; Julian I Rood; Enzo Binotto; Christopher J L Richardson
Journal:  J Antimicrob Chemother       Date:  2003-10-16       Impact factor: 5.790

8.  Molecular characterization of rifampin-resistant Neisseria meningitidis.

Authors:  P E Carter; F J Abadi; D E Yakubu; T H Pennington
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Early treatment with parenteral penicillin in meningococcal disease.

Authors:  K Cartwright; S Reilly; D White; J Stuart
Journal:  BMJ       Date:  1992-07-18

10.  Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000.

Authors:  Muhamed-Kheir Taha; Dario Giorgini; Magaly Ducos-Galand; Jean-Michel Alonso
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

View more
  4 in total

1.  Combined real-time PCR and pyrosequencing strategy for objective, sensitive, specific, and high-throughput identification of reduced susceptibility to penicillins in Neisseria meningitidis.

Authors:  Sara Thulin; Per Olcén; Hans Fredlund; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

2.  Total variation in the penA gene of Neisseria meningitidis: correlation between susceptibility to beta-lactam antibiotics and penA gene heterogeneity.

Authors:  Sara Thulin; Per Olcén; Hans Fredlund; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis.

Authors:  Muhamed-Kheir Taha; Julio A Vázquez; Eva Hong; Desiree E Bennett; Sophie Bertrand; Suzana Bukovski; Mary T Cafferkey; Françoise Carion; Jens Jørgen Christensen; Mathew Diggle; Giles Edwards; Rocío Enríquez; Cecilia Fazio; Matthias Frosch; Sigrid Heuberger; Steen Hoffmann; Keith A Jolley; Marcin Kadlubowski; Amel Kechrid; Konstantinos Kesanopoulos; Paula Kriz; Lotte Lambertsen; Ileanna Levenet; Martin Musilek; Metka Paragi; Aouatef Saguer; Anna Skoczynska; Paola Stefanelli; Sara Thulin; Georgina Tzanakaki; Magnus Unemo; Ulrich Vogel; Maria Leticia Zarantonelli
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

4.  Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005.

Authors:  Mignon du Plessis; Anne von Gottberg; Cheryl Cohen; Linda de Gouveia; Keith P Klugman
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.